Allergan depression treatment fails studies, shares slip

87

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker’s shares down nearly 4 percent after the bell.

http://feeds.reuters.com/~r/reuters/healthNews/~3/q05Cd-YYSSc/allergan-depression-treatment-fails-studies-shares-slip-idUSKCN1QN2RA